Overview

• Tirzepatide significantly reduces the number of sleep interruptions in patients with obstructive sleep apnea (OSA).
• The drug also aids in weight loss and improves cardiovascular health, offering a multifaceted treatment approach.
• Phase III trials included 469 participants across nine countries, showing promising results over a 52-week period.
• The study suggests that tirzepatide could be an alternative to CPAP machines, which require consistent use.
• Shares of companies producing traditional sleep apnea treatments dropped following the trial results.